



## **WPD Pharmaceuticals Announces First Two Sites Initiated In Poland In Clinical Trial of Berubicin In The Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)**

**VANCOUVER, British Columbia, December 19, 2022 - WPD Pharmaceuticals Inc.** (CSE: WBIO) (FSE: 8SV1) (the “**Company**” or “**WPD**”) a clinical-stage pharmaceutical company announces that first two sites have been initiated in multicenter, open-label, Phase 1B/2 efficacy and safety study of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy (or futility) of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose (RP2D) identified in Phase 1 study (7.5 mg/m<sup>2</sup> Berubicin HCl), on the endpoint of ORR in up to approximately 61 patients. This is very important step in Berubicin clinical development. As per today these two Sites are ready to actively recruit patients into the study.

Four Polish clinical sites have been contracted for the purpose of this clinical trial. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. More data could be found under the link below:

<https://clinicaltrials.gov/ct2/show/NCT04915404?term=WPD201&draw=2&rank=1>

WPD has a sublicense for Berubicin from CNS Pharmaceuticals Inc. Sublicense allows WPD geographic exclusivity for development and marketing in a region consisting of select countries in Eastern Europe and Central Asia.

Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs, effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals, Inc demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.

### **About WPD Pharmaceuticals**

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 9 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes about 29 countries in Europe and Asia, including Russia, depending on the compound.

### **On Behalf of the Board**

*'Mariusz Olejniczak'*

Mariusz Olejniczak  
CEO, WDP Pharmaceuticals

### **Contact:**

Investor Relations  
Email: [investors@wpdpharmaceuticals.com](mailto:investors@wpdpharmaceuticals.com)  
Tel: 604-428-7050

Web: [www.wpdpharmaceuticals.com](http://www.wpdpharmaceuticals.com)

### **Cautionary Statements:**

*Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts any responsibility for the adequacy or accuracy of this release.*

*This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include that WPD's is expected to be continue Phase 1B/2 clinical trial. These forward-looking statements reflect current expectations of the Company, based on information currently available to management and are subject to number of risks and uncertainties that may cause outcomes to differ materially from those projected. Factors which may prevent the forward-looking statement from being realized is that the drug compounds may not provide the benefits expected and we may not develop them further; competitors or others may successfully challenge a granted patent and the patent could be rendered void, WPD may not complete the financing for this study or there may be no patient to be recruited. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at [www.sedar.com](http://www.sedar.com). Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they do not guarantee future performance and, accordingly, they should not be relied upon, and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.*

